{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "kanaan2011",
      "version": "1.0.0",
      "authors": "Lingling Xu",
      "description": ""
    },
    "namespace_url": {
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mesh-names.belns",
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "GFAM": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns",
      "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns",
      "INTERPRO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns"
    },
    "namespace_pattern": {
      "DNSNP": "rs[0-9]+",
      "HBP": ".*",
      "TAXONOMY": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {},
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/kanaan2011.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "I-2",
      "id": "94ed115c12bb1b36cff4f84f41521cc451873c48265919ba553ca4e5735bd2424dc664d915f9145e747bad1f10cba0a822c43e11998330afbf02471c38b403a9"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "ING-135",
      "id": "01a4af6caf26b61d6ec1bb7c4844b8d17e328d78ba86857c4da618d1dabeb6d1793f71756723e0f594ef3e1c197f8b8d4d519cbb9463aebbc91faca71abffe8b"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "anterograde axonal protein transport",
      "id": "8f3fac5a50a55c8d864f449be04fec4b2e6e93b959efd6c6f00c776203619d6d0aeac89e4478d892fd7c7391b455e698e63afe4817e761faae3d76149891ef00"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "axonal transport",
      "id": "05b46e2a47c4835f765deb7eb33b970b7abbb53b690b7881e2beda6bc739337253a12aaafa51ebf63ed9f7ad7f09bcd7f5ce4fda7373ed3f4f0eadedaf2c14d0"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "retrograde axonal protein transport",
      "id": "6bea952f92c4e84e44e4aa46ae11fd038e397f0c64414ba3d02f553a3e6192a4339d5384567f9fc2f7b9979be7f4c960652dcf9907c36c5a87a2c8f383a39ff9"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HBP",
          "name": "6D tau",
          "variants": [
            {
              "kind": "frag",
              "start": 2,
              "stop": 18
            }
          ],
          "id": "05a177cfa46adbb0cd50be682e11092a9333ad2251e684e3fb95cd47821711c35f48acd4ff00d25ac8aa68bed1fa990e7c0cb1a353c190cc4ae7b206ea296525"
        },
        {
          "function": "Protein",
          "namespace": "HBP",
          "name": "PAD",
          "id": "0141ea4b99f008acb5781e2541436f974ce67711a953b21aed1fe18cbf2972ee21cbb7e73c540e72cfbd78c8af5d2f3c280d74fe5bea3e06a7eb443007b3d8f2"
        }
      ],
      "id": "afb2ed0559c44f8dd88bcafdd02f1a856ded91c6bab9f9233518e6795467afabcecb3db1343e4762ef65441d83ce967b934d1ee7158f91a70d35eff072565634"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "6D tau",
      "id": "b22576f7e78b628b443db98126bbcdf3a6492eff1f43aa53d2413d263754926554988a093f3bfc235de3b10005ce23711ba93eb54fcfad95d83313d3f0847a93"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "6D tau",
      "variants": [
        {
          "kind": "frag",
          "start": 2,
          "stop": 18
        }
      ],
      "id": "05a177cfa46adbb0cd50be682e11092a9333ad2251e684e3fb95cd47821711c35f48acd4ff00d25ac8aa68bed1fa990e7c0cb1a353c190cc4ae7b206ea296525"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "6P tau",
      "id": "b287bad37c94c4a941c77344f43adf04ef619b51a1dc6ef71fec23a5998bc6f8f111191b4508ef009f068b81eeb6e63e27275c981d3ed8899ac62906e9d0af7f"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "AT8 tau",
      "id": "90ab58611a58c3554181e20ca7cfd44a0e83b974cf634281e3894999343f486dabac3cde6957dd0ad4808010b8db7cc57ddee8e209ba31c078df8e5f6c51f053"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "AT8 tau",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "64541a31527aae2288a7fdfde43b8120d01ee44f88f8b705beb605d5ec19432ebf43ed48c81b24924214c153d5312bc32e4e519030f1a490e51ceda5f3ce5c60"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "delta 144-273 tau",
      "id": "f968379bebc6c0e360d27ecd8331bff8e573835d5a0356d42596da7d8772ecdfe4a11fbe0d6af365425af0d9364b688316a23e5da07a5125a86ec42db8874be3"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "endogenous axoplasmic phosphatases",
      "id": "3f6aa7832ebc0a4102511dab8248ed8a48878ef167fec0c0fd264d8aea1ae73aa4abcb75205cda34ece80a0c65b34e32e0835fc8bd971d54661665fd7605fb36"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "PAD",
      "id": "0141ea4b99f008acb5781e2541436f974ce67711a953b21aed1fe18cbf2972ee21cbb7e73c540e72cfbd78c8af5d2f3c280d74fe5bea3e06a7eb443007b3d8f2"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "TNT1",
      "id": "4c72a7ff9320d936bcb9ce511aed3f0e41c8957bc29400abdda83cb9031fec74e1e525206ad9b3c349d86609e2aa491c1e86ea8afd3d92ce80b693bd89f386f1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Protein",
      "namespace": "MESH",
      "name": "Glycogen Synthase Kinase 3",
      "id": "94a6f01a71750021347c0e40b7207780721428f264f764d1c569a1511d5f253c1b4a47c11da7937a4efa8a7197424ee0a5494911e3c5c071c755010a8e05ffd7"
    },
    {
      "function": "Protein",
      "namespace": "MESH",
      "name": "Protein Phosphatase 1",
      "id": "1d03e5d8f6b62e98de34ad5cb1ecdc1bbda9cee85cd181aef9d1ee1fd3abdce75deacc3212d839d97e9a657d541c1dceda879a05a61a3dfda23481ebb908a323"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Tauopathies",
      "id": "d2087b32a76c528191af8305652f4664cbeb31b3f4e3f9627aaf61259e271f83a7d1be65f83e9178ccf3811482ece65b940fe4ce9a714b2281f705c0d499502b"
    }
  ],
  "links": [
    {
      "line": 79,
      "relation": "causesNoChange",
      "evidence": "perfusion of full-length WT tau monomers (2 􏰊M) (Fig. 1 A) had no effect on FAT in squid axoplasm (Fig. 2 A), while 6D and 6P tau monomers (2 􏰊M) significantly inhibited anterograde FAT when compared with WT tau monomer (Fig. 2 B, C) or buf- fer controls (data not shown).",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "subject": {
        "modifier": "Translocation"
      },
      "source": 15,
      "target": 3,
      "key": "b7ccd3250c4c1f526fd0c351a45b7a48b1ad085c263662cd48da563e6d20c69a8512f8e2430ffe7b33bb153a9286ed85daa1a9417b760edb1e6e3a3591a683ed"
    },
    {
      "relation": "hasVariant",
      "source": 15,
      "target": 16,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    },
    {
      "line": 80,
      "relation": "decreases",
      "evidence": "perfusion of full-length WT tau monomers (2 􏰊M) (Fig. 1 A) had no effect on FAT in squid axoplasm (Fig. 2 A), while 6D and 6P tau monomers (2 􏰊M) significantly inhibited anterograde FAT when compared with WT tau monomer (Fig. 2 B, C) or buf- fer controls (data not shown).",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 6,
      "target": 2,
      "key": "736d19a5f69b118d85c6f0e8d7b7176171593e6761cf5bc6d475427bacb809e33c9e70d208c6a82105547be3d99e8dce3611f734e7c47a87cbe69cd914dbf926"
    },
    {
      "line": 88,
      "relation": "decreases",
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mech- anism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 6,
      "target": 2,
      "key": "32810149c1cc37bb7a507de5e7d1b34c1605d8ebd9e43e9c45dd827b3b67edd96f73192860cd49b46b908a63ea4498f0cecda4275c1f8df2c25481ddec17d8a6"
    },
    {
      "line": 84,
      "relation": "causesNoChange",
      "evidence": " Neither 6D nor 6P tau (Fig. 2D) had an effect on retrograde FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 6,
      "target": 4,
      "key": "d71dd426d5bfc4e79c65ae684f093ed0f550e62bdb1a2380f2ab9a95a634a28ac75048d90eaac68cb941d81bcd0b53fc89ae089120288659c9467ae0122bb498"
    },
    {
      "line": 89,
      "relation": "increases",
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mech- anism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 18,
      "key": "e46818cbf98682453d4bce6d394626865316038c46c351bbcaf57cc5f84935b3407396df6685e0614e84642f8dd6aea030e3412203bd92862c25bfa52ef4fae8"
    },
    {
      "line": 90,
      "relation": "increases",
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mech- anism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 17,
      "key": "3e7c30a12c3b0a734dc315456d8a36c82b18293163e2ada001126202657c2cad7fef60532e6c4120bec6f54ed0192f0061d055c010317448f06de93bc01ec15e"
    },
    {
      "relation": "hasVariant",
      "source": 6,
      "target": 7,
      "key": "4b81846b4d371f5186ed4b051f31ddd321cbcc03f76ee6b519f544dabb4d394550633ff59f7f16182bd24eaff91f33a8adb5e73d9d4e345ba3414039fefb4a4e"
    },
    {
      "line": 95,
      "relation": "association",
      "evidence": "As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 7,
      "key": "0974bb5fe5df393c83cb21d8598f4f50602747577e7e0a585174303626844497ddc3ae009b76200d2ff4a17e4219dd5b968d45f30365aa6b878dc9a02bf63e2a"
    },
    {
      "line": 96,
      "relation": "association",
      "evidence": "As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 2,
      "target": 7,
      "key": "136b804f9df87aee1b3bf7a821989e84aae52f1f7ec2e4e6c65aae3030d46449d42317db978aba8af1ab609a9adbe2087885dcbf35e174d3bae68b417f0c95bb"
    },
    {
      "line": 81,
      "relation": "decreases",
      "evidence": "perfusion of full-length WT tau monomers (2 􏰊M) (Fig. 1 A) had no effect on FAT in squid axoplasm (Fig. 2 A), while 6D and 6P tau monomers (2 􏰊M) significantly inhibited anterograde FAT when compared with WT tau monomer (Fig. 2 B, C) or buf- fer controls (data not shown).",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 8,
      "target": 2,
      "key": "5c7ebdf4a8e007afe22d5bdf33da5151827140f8faaffea354bfa2e0dea26e5e56b57f565efad63ea3c2680cd626ac185ab7d49365bdb5d999f85f27fe8fc30a"
    },
    {
      "line": 85,
      "relation": "causesNoChange",
      "evidence": " Neither 6D nor 6P tau (Fig. 2D) had an effect on retrograde FAT",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 8,
      "target": 4,
      "key": "542c48ae4d35bb51f78588234a71e9fbdeae1ec1f63505817cd910408591817d8bc9cb44df8dba7b8b630eca24a8c181461715fb93caaeae4254ef534b3ccb7a"
    },
    {
      "line": 91,
      "relation": "decreases",
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mech- anism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 18,
      "target": 2,
      "key": "8a6b8d69de281b0d3d0bfb9721f8d0d893eb9634f8c9074b36c4b07c839649afba757019accbccb176ec630969340e31c9eda222f026da240aa74c0d88f14f91"
    },
    {
      "line": 92,
      "relation": "decreases",
      "evidence": "Together, these data demonstrate that, as posited for aggregated tau (LaPointe et al., 2009), short N-terminal isoforms of tau inhibit anterograde FAT by a mech- anism involving activation of PP1 and GSK3 that is independent of microtubule binding.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 2,
      "key": "867451d7c126bc6ab4224af219e9b4fbc7862ecae68cc24382f214473eb89cfd7a50e344bc6073ffe780a2b3831ff59b97e1c7e7f567f03fe2bc6b9d9a3b83c3"
    },
    {
      "line": 95,
      "relation": "association",
      "evidence": "As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 6,
      "key": "21fb36452f84a5fb07628c97ef219ef9bd44762133c754f470ef4e12b6ad87f4467fa12e54506f6b2dccd0dc8ff358afc200ff1e20cf478125696251223dacc1"
    },
    {
      "line": 96,
      "relation": "association",
      "evidence": "As observed with 􏰁2–18 tau aggregates (LaPointe et al., 2009), monomeric 􏰁2–18 6D tau showed no effect on FAT (Fig. 4 A, D), demonstrating that PAD is necessary for 6D tau- mediated inhibition of anterograde FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 7,
      "target": 2,
      "key": "7b6844a86fb42c038b9f8bb0dc455ad7e06e9f5ed192c79d6eaebbbd1583777f23b60fe712c94782a320388481a4aac1f1a01afbed55e9315b5d1511bd9765d6"
    },
    {
      "line": 99,
      "relation": "increases",
      "evidence": "The PAD peptide selectively in- hibited anterograde FAT (Fig. 4 B, D), but not retrograde FAT (Fig. 4B,E).",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 7,
      "target": 2,
      "key": "0f7f1752900e0e10c926de4b618f1d19875df07d7d62ca6cafde134d3208e15f452a1074ad284c7ec0d05a739c0d458e64264409c47f9e29562dfd92995caa1a"
    },
    {
      "line": 119,
      "relation": "increases",
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an- terograde FAT by activating the PP1–GSK3 cascade.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 7,
      "target": 2,
      "key": "f4b469a02fb68d71041269c22f1030623650c2c1061523bdb7eda0eb6af75c637ad09252095b4c6610e6c4ebec02e0cf60d7c2401101473de7c3488d1a6fdc71"
    },
    {
      "line": 100,
      "relation": "causesNoChange",
      "evidence": "The PAD peptide selectively in- hibited anterograde FAT (Fig. 4 B, D), but not retrograde FAT (Fig. 4B,E).",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 7,
      "target": 4,
      "key": "504a1df2ab84c904d62be5da4a967081e4d01740f20ff87a178d120c67a316d0b3d9c92aab1edbb7382990ab29e24b017eac2d888a4c594fb0745a53e9a766b1"
    },
    {
      "line": 112,
      "relation": "decreases",
      "evidence": "P-c-Jun was dephosphorylated to a greater extent in PAD peptide-perfused axoplasms than their scrambled peptide- perfused counterpart (Fig. 5F ), suggesting that the PAD peptide induced activation of endogenous axoplasmic phosphatases.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 7,
      "target": 12,
      "key": "0905a598c6ab3afafb7febfb576e454fe637cf27009c1244dc5519b7357e7ee796c79826ea094d1ac9762d2d87ac7cca53e798d6282d8c42354ed3b1c6441180"
    },
    {
      "line": 115,
      "relation": "decreases",
      "evidence": "A trend of elevated GSK3 activity (􏰈32%) relative to PKC activity ( p 􏰄 0.28, paired t test; n 􏰄 3) was observed for axoplasms incubated with the PAD peptide (mean 􏰄 4.9 􏰉 2.5), compared with those incubated with scram- bled peptide (mean 􏰄 3.7 􏰉 1.7), which supports the results from vesicle motility assays. ",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 17,
      "key": "fe568d6287c56b7b30ba6092df2e161499f164d1686c2e1d22778f478cd23e520d6cd392ccb39b6c0b28631bf1f35b808bd1deb09c908fe3b3c4ff472850c3ee"
    },
    {
      "line": 118,
      "relation": "decreases",
      "evidence": " Collectively, these data indicate that PAD is both necessary and sufficient to inhibit an- terograde FAT by activating the PP1–GSK3 cascade.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 17,
      "key": "e9ac5abdab3a9230d67fb7f0e9aa65913754008ff277c05eab86362e4fd19cdeb52e4513b5f285b284c7f82192e5cec34dedc766f9991d55f44f6bafee51f2a9"
    },
    {
      "line": 132,
      "relation": "association",
      "evidence": "To evaluate the relevance of these find- ings in human disease, we generated a novel monoclonal antibody, termed TNT1, which specifically recognizes PAD.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 7,
      "target": 14,
      "key": "627e52444576f92e20b43442e7db1f4d0687f03276e56d2751c9a2462300d11249c4757a0cb4f2199d12e3f921f013ace4561eaeb5b1fa82465286964bed9b74"
    },
    {
      "line": 136,
      "relation": "association",
      "evidence": "These data indicated that increased PAD exposure, as revealed by TNT1 immunoreac- tivity, occurs early in AD and remains present throughout the disease process.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 19,
      "key": "c5bc7d826ae9f02c930341f593d079b1a8daa3bdf2c7d5c16062169abe1ed2ae3f707dbaadb597e0c8a0c09fc70e498e629e7ef99b0537ed62e3d8602cb79e82"
    },
    {
      "line": 139,
      "relation": "association",
      "evidence": " Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD ex- posure in situ.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 19,
      "key": "4c82b78bf71516f490e706e18746078e0f9ce8aaf24235e6537b99a2a94150e1c6e58fb34efc03f2cdcc0848f572355ca42d8cd96205be3b51122aff3326871a"
    },
    {
      "line": 108,
      "relation": "increases",
      "evidence": "Again, coperfusion of the PAD peptide with either I-2 (50 nM) (Fig. 5A) or ING-135 (100 nM) (Fig. 5B) anterograde FAT inhibition. ",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 7,
      "key": "0eee36d1e3151a4108b6cc198c366cb873da60bc488958221d675d9174ba720b8d71489ec5943260045a1cc15e7409b1e586ea2e61079987e1c7e00adfe41924"
    },
    {
      "line": 109,
      "relation": "increases",
      "evidence": "Again, coperfusion of the PAD peptide with either I-2 (50 nM) (Fig. 5A) or ING-135 (100 nM) (Fig. 5B) anterograde FAT inhibition. ",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 7,
      "key": "ce212f9f805b73770823fb7a4f3b75aa60bdedfa616a8906c1f42b042c36b629e78366120c595998dd487c69330d92b01e8e3a7872d9b02fbae866c6176da6c4"
    },
    {
      "line": 122,
      "relation": "decreases",
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 9,
      "target": 2,
      "key": "4326d5f7d9b8758f3032605420d342155b7e71f70ff2226f7baf7b48786e2a208f31c6b7030a0124938ce9c22a78fb8cb28f8525e7afa0655e36d5700c2196d2"
    },
    {
      "line": 123,
      "relation": "causesNoChange",
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 9,
      "target": 4,
      "key": "2fafe7e3554958e9894a4661950222df24d8f1167da87cd722098bfdc2db44feb0854165cfb289ae5ae45bac3a23355cb47650742ac6d23f70b38d3714b54ae5"
    },
    {
      "relation": "hasVariant",
      "source": 9,
      "target": 10,
      "key": "9e8693a5071e732c42990940717bc9cd62ec158c2026455e8df8ed514579b2cbe3eac16619ea5111c4da187b2d6fb400bca787a4171792303b0cd4859d161f51"
    },
    {
      "line": 140,
      "relation": "causesNoChange",
      "evidence": " Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD ex- posure in situ.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 7,
      "key": "e91eca44f4b94ef5e16103387dd5a60d887fcbc3a6cd7d5efd246a4574d21366cf0ca7d3b549913b5fdf09cc0b7eaa0f3b74fc1d8eff9f52ed90d1862dbe51ae"
    },
    {
      "line": 124,
      "relation": "association",
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 10,
      "target": 16,
      "key": "0b3d48a51d8a5f848292a78c3970118d0a817acd00be3c898c5de2a099079450716f7dd47a60232bac5a164006824d221f4f4904dfc97d6d0d800fa891d9b132"
    },
    {
      "line": 125,
      "relation": "association",
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 10,
      "target": 20,
      "key": "1bbfdb5b5a2f8a171e10b7b12f82eea66225270d925b03d49a16be63c076bed27d91b6ada4d742170a5b14fb6e1209e877392f933bbfbd3027c71b8c70865d5d"
    },
    {
      "line": 124,
      "relation": "association",
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 16,
      "target": 10,
      "key": "3285489ccae1d46058954f043ab2031a50abac0592e4f7a78b21f603b59da25517af8516b16743d3dff0c135d49312095bd7bb4bde192f6fa807fe1aacf11f8e"
    },
    {
      "line": 125,
      "relation": "association",
      "evidence": "Soluble AT8 tau monomers inhibited anterograde FAT (Fig. 6 A, C), while retrograde trans- port was unaffected (Fig. 6 A, D). These data indicate that phos- phorylation of tau at the AT8 epitope, which is associated with hyperphosphorylation of tau in AD and other tauopathies, renders soluble monomeric tau capable of inhibiting antero- grade FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 20,
      "target": 10,
      "key": "45e7dfbde185256f1f57d3826db3b55ed3a1e77dcece77bc641185b8c2875945343002249b2164c0e690fb4bf379c5e4cd229ccb3b473feba8e6dc8723444c89"
    },
    {
      "line": 128,
      "relation": "decreases",
      "evidence": " Consistent with our model, 􏰁144 –273 tau monomers significantly inhibited antero- grade FAT (Fig. 6 B, C), while retrograde FAT remained unaf- fected (Fig. 6 B, D).Together, these data indicate that disease- associated modifications and mutations in tau that increase exposure of PAD promote activation of the PP1–GSK3 pathway and inhibition of anterograde FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 11,
      "target": 2,
      "key": "e0e09cf44e8d6563f5c9abb9a45ffe96288afb0cc031fb8d4f4c237dd8cb267dab90aabc19dbb07bb86a598b92213afc482f65eef6b821328c3b57a443f00573"
    },
    {
      "line": 129,
      "relation": "causesNoChange",
      "evidence": " Consistent with our model, 􏰁144 –273 tau monomers significantly inhibited antero- grade FAT (Fig. 6 B, C), while retrograde FAT remained unaf- fected (Fig. 6 B, D).Together, these data indicate that disease- associated modifications and mutations in tau that increase exposure of PAD promote activation of the PP1–GSK3 pathway and inhibition of anterograde FAT.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 11,
      "target": 4,
      "key": "52780aa1e0d5901ec2d65318c49e0d2dcaefd236393beffb313c83ce00e07b5c5e208602c76ca8c71e682010d142b7877047d3535cdd2c04660ba9a9d28bbe57"
    },
    {
      "line": 132,
      "relation": "association",
      "evidence": "To evaluate the relevance of these find- ings in human disease, we generated a novel monoclonal antibody, termed TNT1, which specifically recognizes PAD.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "source": 14,
      "target": 7,
      "key": "c1a355f9887c26db6c2a0f18ef18034c53cabb06a40eb50513da9382ac29a83c8df6a70faf40ac55532cb8a9addeab6d485aab1446ae9396b14cbc9050c47b4d"
    },
    {
      "relation": "hasComponent",
      "source": 5,
      "target": 7,
      "key": "1a8ebb735ff1c48fc3e6b1d101c24b57088d0c9e2aba7b2e154cddc87959540a7debbe404622d3640943e3103a08dff95a434dd0a3cdcb641ea41a5b5ad73902"
    },
    {
      "relation": "hasComponent",
      "source": 5,
      "target": 13,
      "key": "e55b6d7b0d9b9f3cfb8351cb2ff3744730fc4b870b849e659b033a1933198e8e13c57b18a88e051fdb9cc37de152ffa1885308299b6b0b962cfd885f07148e8a"
    },
    {
      "line": 136,
      "relation": "association",
      "evidence": "These data indicated that increased PAD exposure, as revealed by TNT1 immunoreac- tivity, occurs early in AD and remains present throughout the disease process.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 7,
      "key": "58005a095068ec7fe81cc585e678cc9ea7e725b682fcef5dec490566f73f41c5826daecb6e1cd324ea3d5eabd0a4973f63b3d12bd76594b4e5de7348c948b793"
    },
    {
      "line": 139,
      "relation": "association",
      "evidence": " Together, these data suggest that increased PAD exposure represents an early event in AD pathogenesis and that AT8 may not be required for PAD ex- posure in situ.",
      "citation": {
        "type": "PubMed",
        "reference": "21734277"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 7,
      "key": "90a0c8a2fa096915fc0bfc8c0ada4c6e35f608a434370f371df96b3ae2e6f9bedb59d17afaf2efe1ea109e07d723122a2e19a8f1aa7988aea0094f3b9393bb04"
    }
  ]
}